TPTX » Topics » Item 6. Exhibits.

This excerpt taken from the TPTX 8-K filed Dec 20, 2006.

(d) Exhibits

Exhibit Number

 

 

 

Description

10.1

 

Employment Agreements by and between Neil M. Kurtz, M.D. and TorreyPines Therapeutics, Inc. dated December 14, 2006.

 

 

 

10.2

 

Employment Agreements by and between Evelyn Graham and TorreyPines Therapeutics, Inc. dated December 14, 2006.

 

 

 

10.3

 

Employment Agreements by and between Craig Johnson and TorreyPines Therapeutics, Inc. dated December 14, 2006.

 

 

5




This excerpt taken from the TPTX 8-K filed Dec 13, 2006.

(d) Exhibits

Exhibit Number

 

Description

16.1

 

Letter from Eisner LLP to the Securities and Exchange Commission, dated December 13, 2006.

 

 

3




This excerpt taken from the TPTX 10-Q filed Aug 8, 2006.

Item 6. Exhibits.

 
Number   Exhibits


2.1   Agreement and Plan of Merger and Reorganization, dated as of June 7, 2006, between Axonyx Inc. and TorreyPines Therapeutics, Inc. (incorporated by reference to the correspondingly-numbered exhibit to the registrant’s Current Report on Form 8-K filed June 12, 2006)
     
2.2   Form of Voting Agreement, dated as of June 7, 2006, between Axonyx Inc. and certain stockholders of TorreyPines Therapeutics, Inc. (incorporated by reference to the correspondingly-numbered exhibit to the registrant’s Current Report on Form 8-K filed June 12, 2006)
     
2.3   Form of Voting Agreement, dated as of June 7, 2006, between TorreyPines Therapeutics, Inc. and certain stockholders of Axonyx Inc. (incorporated by reference to the correspondingly-numbered exhibit to the registrant’s Current Report on Form 8-K filed June 12, 2006)
     
4.1   Rights Agreement Amendment, dated as of June 7, 2006, to the Rights Agreement, dated as of May 13, 2005, between Axonyx Inc. and The Nevada Agency and Trust Company (incorporated by reference to the correspondingly-numbered exhibit to the registrant’s Current Report on Form 8-K filed June 12, 2006)
     
31.1   Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14 (a), adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
31.2   Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14 (a), adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
32.1   Certification of Chief Executive Officer pursuant to 18 U.S.C Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
32.2   Certification of Chief Financial Officer pursuant to 18 U.S.C Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

20



SIGNATURES

                Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated August 8, 2006.

 
  AXONYX INC.
   
  By: /s/ Gosse B. Bruinsma, M.D.
 
  Gosse B. Bruinsma, M.D.
  President and Chief Executive Officer
   
  By: /s/ S. Colin Neill
 
  S. Colin Neill
  Chief Financial Officer,
  Secretary and Treasurer
  (Principal Financial and Accounting Officer)

21


This excerpt taken from the TPTX 8-K filed Jun 12, 2006.

EXHIBITS

 

Exhibit A

-

Certain Definitions

 

Exhibit B

TorreyPines Stockholders Voting Agreement

 

Exhibit C

Axonyx Stockholders Voting Agreement

 

Exhibit D

-

Form of Warrant

 

Exhibit E

-

Lock-up Agreement

 

Exhibit F

-

Axonyx (and Merger Sub) Tax Representation Letter

Exhibit G

-

TorreyPines Tax Representation Letter

 

 

 

 

 



 

 

This excerpt taken from the TPTX 10-Q filed May 10, 2006.

Item 6.                Exhibits.

 

Number

 

Exhibits

 

 

 

 

 

31.1

 

Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

31.2

 

Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

32.1

 

Certification of Chief Executive Officer pursuant to 18 U.S.C Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

 

 

32.2

 

Certification of Chief Financial Officer pursuant to 18 U.S.C Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

16

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated May 10, 2006.

 

 

AXONYX INC.

 

 

 

By: /s/ Gosse B. Bruinsma, M.D.

 

 

 

Gosse B. Bruinsma, M.D.
President and Chief Executive Officer

 

 

 

By: /s/ S. Colin Neill

 

 

 

S. Colin Neill
Chief Financial Officer,
Secretary and Treasurer
(Principal Financial and Accounting Officer)

 

17

 

 

This excerpt taken from the TPTX 10-Q filed May 10, 2005.

Item 6.             Exhibits.

 
Number Exhibits
 

   
31.1
Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
31.2
Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
32.1
Certification of Chief Executive Officer pursuant to 18 U.S.C Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
 
32.2
Certification of Chief Executive Officer pursuant to 18 U.S.C Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

16



SIGNATURES

                Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated May 10, 2005.

 
  AXONYX INC.
 
  By: /s/ Gosse B. Bruinsma, M.D.
 
   
  Gosse B. Bruinsma, M.D.
President and Chief Executive Officer
   
   
  By: /s/ S. Colin Neill
 
   
S. Colin Neill
Chief Financial Officer,
Secretary and Treasurer
(Principal Financial and Accounting Officer)

17


EXCERPTS ON THIS PAGE:

8-K
Dec 20, 2006
8-K
Dec 13, 2006
10-Q
Aug 8, 2006
8-K
Jun 12, 2006
10-Q
May 10, 2006
10-Q
May 10, 2005

RELATED TOPICS for TPTX:

"Item 6. Exhibits." elsewhere:

ABAXIS (ABAX)
Biotie Therapies Corp. (BITI)
BioMimetic Therapeutics (BMTI)
Dynavax Technologies (DVAX)
IMMUNE PHARMACEUTICALS INC (EPCT)
Genelabs Technologies (GNLB)
ImmuCell (ICCC)
Icagen (ICGN)
Immunomedics (IMMU)
Infinity Pharmaceuticals (INFI)
ISTA Pharmaceuticals (ISTA)
MEDICURE (MCU)
Memory Pharmaceuticals (MEMY)
Monogram Biosciences (MGRM)
Myriad Genetics (MYGN)
Neogen (NEOG)
Neuro-Hitech, Inc. (NHPI)
Nymox Pharmaceutical (NYMX)
Acer Therapeutics Inc. (OPXA)
Orchid Cellmark (ORCH)
VIVEVE MEDICAL, INC. (PLC)
Quidel (QDEL)
Sunesis Pharmaceuticals (SNSS)
Molecular Templates, Inc. (THLD)
Trinity Biotech (TRIB)
Meridian Bioscience (VIVO)
ZIOPHARM ONCOLOGY (ZIOP)
CORD BLOOD AMERICA (CBAI)
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki